Merck & Company Inc (MRK)vsNeuraxis, Inc. (NRXS)
MRK
Merck & Company Inc
$120.79
-3.46%
HEALTHCARE · Cap: $285.64B
NRXS
Neuraxis, Inc.
$6.84
-5.91%
HEALTHCARE · Cap: $84.21M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 1535997% more annual revenue ($65.77B vs $4.28M). MRK leads profitability with a 13.6% profit margin vs -170.1%. MRK earns a higher WallStSmart Score of 50/100 (D+).
MRK
Hold50
out of 100
Grade: D+
NRXS
Avoid22
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Margin of Safety
-80.2%
Fair Value
$2.58
Current Price
$6.84
$4.26 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Revenue surging 79.5% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Trading at 13.7x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : NRXS
The strongest argument for NRXS centers on Revenue Growth, Debt/Equity. Revenue growth of 79.5% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : NRXS
The primary concerns for NRXS are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
MRK profiles as a value stock while NRXS is a hypergrowth play — different risk/reward profiles.
NRXS carries more volatility with a beta of 1.48 — expect wider price swings.
NRXS is growing revenue faster at 79.5% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 22/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Neuraxis, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
NeurAxis, Inc. is a neuromodulation therapy device company in the United States. The company is headquartered in Versailles, Indiana.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?